RecruitingPhase 3NCT04996017
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Intervention
- Atezolizumab 1200 mg in 20 ML Injection(drug)
- Enrollment
- 162 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2029
Study locations (19)
- Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori - Irccs, Meldola, ITAòY, Italy
- Ospedaliera SS Antonio e Biagio e Cesare Arrigo di Alessandria, Alessandria, Italy
- Istituto Tumori Bari, Bari, Italy
- Azienda Ospedaliera Universitaria Policlinico- Vittorio Emanuele Catania, Catania, Italy
- Ospedale Ss Annunziata, Chieti, Italy
- Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy
- Villa Scassi, Genova, Italy
- Ospedale Dell'Angelo, Mestre, Italy
- Azienda Ospedaliera Universitaria Di Modena, Modena, Italy
- Aorn Ospedale Dei Colli, Naples, Italy
- A.O.U. San Luigi Gonzaga, Orbassano, Italy
- Istituto Oncologico Veneto, Padua, Italy
- Azienda Ospedaliera Universitaria Di Parma, Parma, Italy
- Policlinico San Matteo, Pavia, Italy
- AUSL/IRCCS di Reggio Emilia, Reggio Emilia, Italy
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04996017 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited